Ultragenyx Pharmaceutical (RARE) Return on Equity: 2017-2025
Historic Return on Equity for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Sep 2025 value amounting to -7.24%.
- Ultragenyx Pharmaceutical's Return on Equity fell 581.00% to -7.24% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.24%, marking a year-over-year decrease of 581.00%. This contributed to the annual value of -2.15% for FY2024, which is 22.00% down from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its Return on Equity stood at -7.24% for Q3 2025, which was down 100.36% from -3.62% recorded in Q2 2025.
- Ultragenyx Pharmaceutical's 5-year Return on Equity high stood at -0.19% for Q1 2021, and its period low was -7.95% during Q3 2023.
- Moreover, its 3-year median value for Return on Equity was -2.95% (2024), whereas its average is -3.68%.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's Return on Equity crashed by 676bps in 2023 and then soared by 651bps in 2024.
- Ultragenyx Pharmaceutical's Return on Equity (Quarterly) stood at -0.49% in 2021, then slumped by 124bps to -1.73% in 2022, then slumped by 222bps to -3.95% in 2023, then skyrocketed by 206bps to -1.90% in 2024, then plummeted by 581bps to -7.24% in 2025.
- Its last three reported values are -7.24% in Q3 2025, -3.62% for Q2 2025, and -2.76% during Q1 2025.